Journal of Oncology / 2014 / Article / Tab 2

Review Article

The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis

Table 2

Design and characteristics of trials included in the systematic review and metaanalysis.

Author (trial)YearNumber of patientsDosage of bisphosphonateCombination therapyDurationMedian follow up (months)InterventionJadad score

Lombart et al. (E-ZO FAST)20095274 mg IV every 6 months2.5 mg letrozole daily5 years36Immediate ZOL 4 mg every 6 months, delayed ZOL 4 mg every 6 months3
Bundred et al. (ZO FAST) [17]200810654 mg IV every 6 months2.5 mg letrozole daily5 years48Immediate ZOL 4 mg every 6 months, delayed ZOL 4 mg every 6 months4
Brufsky et al. (Z FAST) [16]20076024 mg IV every 6 months2.5 mg letrozole daily5 years54Immediate ZOL 4 mg every 6 months, delayed ZOL 4 mg every 6 months4
Van Poznak et al. (SABRE trial) [18]2010234Residronate 35 mg per week1 mg Anastrozole daily2 years24Anastrozole + residronate,
anastrozole + placebo
4
Markopoulos et al. (ARBI trial) [20]2010213Residronate 35 mg per week1 mg Anastrozole daily3 years36Anastrozole + residronate, anastrozole + placebo3
Lester et al. (ARIBON trial) [19]2008131Ibandronate 150 mg every 28 day1 mg Anastrozole daily2 years24Anastrazole + ibandronate,
anastrozole + placebo
3